^
    Back
    Association details:
    Biomarker:ERCC2 mutation
    Cancer:Bladder Cancer
    Drug:cisplatin (DNA synthesis inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Eur Urol
    Title:

    Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer

    Published date:
    08/11/2022
    Excerpt:
    ...we observed a positive association between deleterious mutations in ERCC2 and pathological response...This study confirmed that patients with bladder cancer with a mutation in the ERCC2 gene often respond to chemotherapy.
    Secondary therapy:
    Chemotherapy
    DOI:
    10.1016/j.eururo.2022.07.023